Humacyte, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Laura E. Niklason
- Full Time Employees
- 184
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2525 East North Carolina Highway 54 Durham NC United States of America 27713
- IPO Date
- Dec 1, 2020
- CIK
- 0001818382
- Website
- humacyte.com
- Similar Companies
- Business
- Humacyte, Inc. (Nasdaq: HUMA) develops and manufactures universally implantable, off-the-shelf, bioengineered human tissues and organs utilizing a proprietary scalable bioengineering platform that transforms human cells into acellular tissue engineered vessels (ATEVs) and advanced constructs designed to treat injury, disease, and chronic conditions with low infection rates and regenerative potential. Core products and investigational candidates include Symvess (acellular tissue engineered vessel-tyod), FDA-approved in December 2024 for extremity vascular trauma repair; ATEVs in Phase 3 for dialysis arteriovenous access (meeting co-primary endpoints in V007 trial), peripheral artery disease, coronary artery bypass grafting, and pediatric heart disease; advanced organ systems such as BioVascular Pancreas for type 1 diabetes and lung applications; and advanced tissue constructs for urinary conduits, tracheal replacement, and esophageal replacement. The company, founded in 2004 and headquartered in Durham, North Carolina, operates primarily in the United States with a global intellectual property footprint spanning the United States, Europe, Canada, and Australia; it targets vascular surgery, trauma centers, dialysis patients, military medical facilities, and regenerative medicine markets. Recent developments encompass the FDA's completion of Symvess product batch release review enabling commercial shipments, commencement of Symvess market launch and first sales in early 2025, a $46.7 million public offering to extend cash runway, cost reductions to align with commercial and pipeline priorities including a planned supplemental BLA for dialysis in H2 2026 and IND filing for CABG, and expansion of intellectual property in September 2025 with a new U.S. patent for bioengineered esophagus alongside coverage for trachea and urinary conduits to support pipeline advancement and potential corporate partnerships.
Company News
Humacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA Discussions
Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMA
Humacyte Announces Lancet Digital Health Publication of V007 Phase 3 Hemodialysis Access Trial Results
Head to Head Comparison: Denali Therapeutics (NASDAQ:DNLI) versus Humacyte (NASDAQ:HUMA)
Board-Certified Vascular and Endovascular Surgeon Performs First Commercial Symvess® Implantation; Cites Bioengineered Blood Vessel as “Revolutionary Advancement”
Humacyte, Inc. (HUMA) Q2 2026 Earnings Call Transcript
Humacyte, Inc. (HUMA) Reports Q2 Loss, Misses Revenue Estimates
Humacyte Q2 Earnings Call Highlights
Humacyte Announces Second Quarter 2026 Financial Results and Provides Business Update
Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMA
Humacyte To Announce 2026 Second Quarter Financial Results and Provide Business Update on August 12, 2026
Humacyte, Inc. (HUMA) Rises As Market Takes a Dip: Key Facts
Humacyte, Inc. (HUMA) Stock Dips While Market Gains: Key Facts
Humacyte Announces FDA Acceptance of IND for First-In-Human Clinical Study of CTEV for Coronary Artery Bypass Grafting
Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know
Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights
Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know
Humacyte Appoints Key Nephrologists as Advisors to Prepare for Planned Commercialization of the ATEV in Dialysis Access
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why
Here's Why Humacyte, Inc. (HUMA) Fell More Than Broader Market